DIRS.INFO The most relevant business & tech news

Stocks tumbled on Friday as the post-election rally fizzled and investors fretted over the path of interest rates. The S&P 500 slipped 1.32% and closed at 5,870.62, while the Nasdaq Composite fell 2.24% to 18,680.12. Declines in pharmaceutical stocks weighed on the 30-stock Dow and broader S&P 500, with Amgen down about 4.2% and Moderna off by 7.3%. The information technology sector of the S&P 500 was the worst performing corner of the market, down more than 2% as Nvidia, MetaPlatforms, Alphabet and Microsoft tumbled. The S&P 500 posted a weekly loss of 2.1%, while the Nasdaq Composite slid about 3.2%.

Persons: Stocks, Donald Trump, Robert F, Kennedy Jr, Tesla, ”, Kristy Akullian, “, Jerome Powell, Susan Collins, Dow Jones Organizations: Dow Jones Industrial, Nasdaq, Dow, Moderna, Department of Health, Human Services, P Biotech, Nvidia, Microsoft, Trump Trade, ” Traders, Federal, Boston, Street Locations: Americas, BlackRock

☆ Evercore ISI says three years of biotech underperformance may be ending, gives its 5 favorite stocks
▼ + stars: | 2024-05-14 | by ( Hakyung Kim | ) www.cnbc.com time to read: +2 min

"After 3 years of painful underperformance, winter is finally thawing and spring just might be in the air," analyst Cory Kasimov wrote in a Monday note. Biotech stocks broadly peaked in early 2021 when interest rates were at a trough, Kasimov noted. While biotech stocks are sensitive to interest rates, the analyst believes most of the group's other catalysts — such as mergers and access to capital — remain "relatively consistent." XBI YTD mountain SPDR S & P Biotech ETF performance year to date The sector is opportune for investors looking for "a stock picker's market," according to Kasimov. With this in mind, he named seven stocks to his core initial list, which he named "The Magnificent Seven."

Persons: Cory Kasimov, Kasimov, We've, Neurocrine, — CNBC's Michael Bloom Organizations: ISI, Biotech, P Biotech, Moderna Locations: —

Hedge fund managers gathered Wednesday at the 2024 Sohn Investment Conference in New York to share their best investment ideas. It kicked off with "Next Wave Sohn," a session that features ideas from rising stars within the hedge fund industry. Endocrinology is an $8 billion market, but the cumulative market size, including the company's future therapy targets, is upward of $200 billion, which includes estimates for future obesity drugs, the investor said. It has CA$75 billion market cap with an "unbelievable record of success," according to the investor. The short seller noted that the company has a $5 billion market cap with about $4.8 billion of debt.

Persons: Sohn, Eric Wolff, Wolff, Michelle Ross, Cushing, Ross, Eli Lilly, Crinetics, XBI, Nikhil Daftary, Alimentation, Daftary, Chris Drose, Nate Koppikar, Fahmi Quadir Organizations: Investment, Gumshoe Capital Management Investment, Pason Systems Energy, Pason Systems, Gumshoe Capital Management, StemPoint, Pharmaceuticals, Crinetics Pharmaceuticals, StemPoint Capital, Endocrinology, Novo Nordisk, P Biotech, NK Capital Investment, NK Capital, Starbucks, McDonalds, Bleecker Street Capital, Orso Partners, Justice Department, Federal Trade Commission, Safkhet, Global Education Locations: New York, Canada, U.S

☆ Stocks making the biggest moves midday: Nvidia, Coinbase, Oracle, Bally's and more
▼ + stars: | 2024-03-11 | by ( Sarah Min | ) www.cnbc.com time to read: +2 min

Oracle — Shares added 1.6% ahead of the software giant's fiscal third-quarter earnings report due after the bell. Analysts polled by FactSet are expecting earnings per share of $1.38 and revenue of $13.29 billion. New York Community Bancorp — The regional bank stock dropped 4.8%, extending losses after Friday's more than 6% drop. Moderna — The stock jumped more than 8% in midday trading, putting it on track for its biggest one-day gain since December. Duolingo — Shares rose 3.6% after JPMorgan initiated coverage of the online learning platform with an overweight rating, forecasting "premium" revenue growth that could substantially drive up Duolingo's valuation.

Persons: FactSet, Lam, Coinbase, Microstrategy, Jefferies, Eli Lilly, — CNBC's Michelle Fox, Alex Harring, Yun Li, Tanaya Macheel, Pia Singh Organizations: Oracle, Nvidia, Semiconductor, Lam Research, New York Community Bancorp, Moderna, P Biotech, Xcel Energy, Barclays, JPMorgan, PDD Holdings

☆ 23andMe is low on cash and its stock is worth pennies. The CEO wants another chance
▼ + stars: | 2024-02-02 | by ( Nicole Goodkind | ) edition.cnn.com time to read: +8 min

New York CNN —Just three years ago, DNA testing company 23andMe was the golden child of Wall Street and Silicon Valley. In 2018, 23andMe agreed to a five-year exclusive drug development partnership with GSK (formerly GlaxoSmithKline). Genetic testing company 23andMe, once valued at $6 billion, is facing the possibility of delisting from NASDAQ. Justin Sullivan/Getty ImagesSo far, the partnership between GSK and 23andMe has produced more than 50 new drug targets. But drug discovery is a very long process and it can be anywhere from 10 to 15 years on average from target discovery to an FDA-approved drug.

Persons: New York CNN —, 23andMe, Anne Wojcicki, ” Wojcicki, “, Susan Wojcicki, Sergey Brin, Kyle Grillot, Wojcicki, they’ve, ”, we’re, “ We’ve, Steven Mah, TD Cowen, Mah, they’re, Justin Sullivan Organizations: New, New York CNN, Nasdaq, CNN, Stanford, Palo Alto High School, YouTube, Google, 23andMe Inc, Bloomberg, Time Magazine, P Biotech ETF, GSK, GlaxoSmithKline, NASDAQ, Big Pharma, it’s Locations: New York, Silicon Valley, Los Angeles , California, U.S, London, Sunnyvale , California, United States

☆ Analysts love these biotech stocks, giving 4 more than 100% upside
▼ + stars: | 2024-01-25 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S & P Biotech ETF. Potential upside to average price target of more than 40%. Four stocks stood out for being given on average more than 100% potential upside: Humacyte , Marinus Pharmaceuticals , Olema Pharmaceuticals and Ovid Therapeutics . Another three stocks in the screen drew 100% buy ratings from analysts: Ardelyx , Cabaletta Bio and Rocket Pharmaceuticals . Of these three, Rocket Pharmaceuticals got the highest potential upside of 81.4%.

Persons: Marinus, Biomea Organizations: Citi, Federal Reserve, CNBC Pro, Biotechnology, P Biotech ETF, Marinus Pharmaceuticals, Olema Pharmaceuticals, Ovid Therapeutics, Rocket Pharmaceuticals

☆ European markets head for a lower open ahead of ECB rate decision
▼ + stars: | 2024-01-25 | by ( Holly Ellyatt | ) www.cnbc.com time to read: 1 min

The health-care sector may have done poorly in the last couple of years, but analysts are bullish on it right now, citing biotech as an area to watch. "Just two weeks into 2024, the healthcare sector has shrugged off the title of being a notable laggard in 2023," Citi said in a recent note. To look for biotech stocks that did well last year and that analysts are still positive on, CNBC Pro screened the iShares Biotechnology ETF and the SPDR S&P Biotech ETF. Subscribers can read more here. — Weizhen Tan

Persons: Weizhen Tan Organizations: Citi, CNBC Pro, Biotechnology, P Biotech ETF

☆ Hedge fund investor Dan Niles unveils his top picks for 2024, including Amazon and Meta
▼ + stars: | 2024-01-02 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Widely followed investor Dan Niles on Tuesday revealed his top stock picks for 2024, including one of 2023's top performers. The founder and senior portfolio manager of the Satori Fund selected two names from the so-called Magnificent Seven mega-cap tech stocks as his favored shares for the new year — Amazon and Meta Platforms . META 1Y mountain Meta shares 1-year chart ETFs The hedge fund investor is also bullish on SPDR S & P Biotech ETF (XBI), which tracks more than 120 biotech companies. The investor said the top holdings in KWEB — Baidu , Alibaba and Tencent — are so much cheaper than mega-cap names in the Magnificent Seven. "You can buy them at 13 times P/E off 24 numbers for comparison, The Magnificent Seven, you're paying 34 times," he said.

Persons: Dan Niles, Satori, Niles, Apple, they're, we've Organizations: Satori Fund, Apple, Barclays, CNBC, Meta, P Biotech, KraneShares CSI China Internet, Baidu

☆ Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
▼ + stars: | 2023-12-28 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +8 min

Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. "We expect this environment to continue but look forward to the prospect of lower interest rates in 2024." When that happens, Canaccord Genuity said to expect a "strong rally across the biotech sector rewarding innovative, but riskier assets." Analysts have said the rich price reflects the opportunity for ImmunoGen's Elahere cancer treatment , which has quickly established itself as the standard of care for types of ovarian cancer. 'Oversold and cheap' In a research note Friday, Jefferies analyst Michael Yee said "a significant short squeeze" was helping biotech stocks in the fourth quarter.

Persons: Dan Lyons, Janus Henderson, John Newman, Canaccord Genuity, Janus, Lyons, Bristol Myers Squibb, Karuna, AstraZeneca, Eli Lilly, AbbVie, Jonathan Miller, Miller, bode, Jonathan Krinsky, Krinsky, BTIG's, Jefferies, Michael Yee, Yee, NASH, Madrigal, we're, David Risinger, — CNBC's Michael Bloom Organizations: Drug, Federal, Bristol Myers, Karuna Therapeutics, CART, Bristol Myers Squibb, Cerevel Therapeutics, Securities and Exchange Commission, pharma, P Biotech, Nasdaq Biotech, Apogee Therapeutics, Madrigal Pharmaceuticals, Madrigal, resmetirom, Vertex Pharmaceuticals, Leerink Partners Locations: ImmunoGen

☆ Biotech stocks jump on AbbVie deal to buy cancer drugmaker ImmunoGen for $10 billion
▼ + stars: | 2023-11-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Biotech stocks rose Thursday as AbbVie announced plans to buy cancer drug developer ImmunoGen for $10.1 billion. ImmunoGen develops cancer drugs called antibody-drug conjugates, or ADCs, which are designed to directly kill cancer cells and spare healthy ones. Shares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the news of the buyout. The SPDR S&P Biotech ETF , which focuses on small and midsize biotech companies, rose 3% Thursday. Under the terms of the deal, AbbVie will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday's closing price.

Persons: AbbVie, ImmunoGen, Michael Schmidt Organizations: Biotech, Mersana Therapeutics, ADC Therapeutics, P Biotech ETF, Nasdaq Biotechnology, ImmunoGen, Pfizer, Merck, CNBC PRO Locations: ADCs

☆ Citi is so bullish on this biotech stock it gives it 800% potential upside
▼ + stars: | 2023-11-29 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

Citi is so bullish on one biotech firm that it has given its shares a target price that represents around 800% upside. In a Nov. 22 note, Citi gave the stock a buy rating and a price target of $90, representing potential upside of around 818% from Tuesday's price. However, the bank cautioned that the stock is high risk, given the "typical volatility" of biotech stocks and uncertainty associated with clinical trials. According to FactSet, analysts covering the stock give it average price target upside of 385% and a buy rating of 88%. On FactSet, the highest estimate came from Oppenheimer, which gives it potential upside of over 600%.

Persons: —, Oppenheimer, — CNBC's Michael Bloom Organizations: Citi, Citi isn't, BMO Capital Markets, BMO, P Biotech ETF, Biotech Locations: U.S

☆ This European biotech company could rally nearly 45%, says Morgan Stanley
▼ + stars: | 2023-10-13 | by ( Hakyung Kim | ) www.cnbc.com time to read: +1 min

Recent data for cancer treatment manufacturer MorphoSys AG suggests the German biotech's shares could see a significant rally, according to Morgan Stanley. "Despite increasing competition, our updated analysis suggests peak global sales of $1.6bn for pelabresib," analyst James Quigley wrote in a Friday note. "In addition, while some clinical risk remains, the data so far suggests that MANIFEST-2 has a good chance of success, which should drive significant upside in the shares," Quigley said. Shares have sold off nearly 25% since mid-September, compared to the Nasdaq Biotechnology Index down 4% over the same period. MOR XBI YTD mountain MorphoSys vs SPDR S & P Biotech ETF in 2023.

Persons: Morgan Stanley, James Quigley, Quigley, SPDR, — CNBC's Michael Bloom Organizations: MorphoSys, pelabresib, Nasdaq, MF, P Biotech

☆ If you sold in May, it's time to start buying again, says the Stock Trader's Almanac
▼ + stars: | 2023-10-12 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +2 min

A Monday evening note from Almanac editor Jeffrey Hirsch said that the stock market appears to be in the early stages of an end-of-year rally. SPY YTD mountain The S & P 500 is up since May, but did suffer a late-summer swoon. The buy signal could help offset the multiple negatives working against the stock market, including bond yield volatility and the conflict in the Middle East. The Almanac's portfolio changes show an expectation of a broad market rally. The moves include buying the SPDR Dow Jones Industrial Average ETF Trust (DIA) , SPDR S & P 500 ETF Trust (SPY) , and the Invesco QQQ Trust (QQQ) as well as the iShares Russell 2000 ETF (IWM) .

Persons: Jeffrey Hirsch, SPDR, Russell Organizations: Dow Jones, ETF Trust, Trust, P Biotech, Consumer, Vanguard, Index

☆ Rising interest rates are hurting very broad swaths of the stock and bond markets
▼ + stars: | 2023-10-03 | by ( Bob Pisani | ) www.cnbc.com time to read: +3 min

Dozens of stocks and ETFs are hitting 52-week lows on the relentless rise in interest rates. Treasury bond ETFs: New lows iShares 1-3 Year Treasury Bond ETF (SHY) iShares 7-10 Year Treasury Bond ETF (IEF) iShares 10-20 Year Treasury Bond ETF (TLH) iShares 20+ Year Treasury Bond ETF (TLT) It's not just Treasury bonds. Broad bond ETFs: New lows Vanguard Total Bond Market ETF (BND) iShares Core US Aggregate Bond Fund (AGG) Higher rates are affecting other areas of the U.S. economy: look at clean energy and biotech It's simple. Clean energy ETFs: New lows iShares Global Clean Energy (ICLN) VanEck Low Carbon Energy ETF (SMOG) Invesco WilderHill Clean Energy ETF (PBW) Invesco Solar ETF (TAN) It's the same story with biotech. The SPDR S & P Biotech ETF (XBI) , which tracks an equal-weighted index of US biotechnology stocks, is at a 52-week low.

Persons: Schwab, It's Organizations: Vanguard Utilities, Treasury Bond ETF, Bond Market, Bond Fund, NextEra Energy Partners, Clean Energy, Carbon Energy, P Biotech, Biotechnology, Biotech, Verizon, SPDR Telecom, AT, Property, Comerica, Huntington Bancshares Locations: U.S, Orsted, Denmark, REITs

☆ How to Tell Biotech’s Likely Winners From Losers
▼ + stars: | 2023-04-18 | by ( David Wainer | ) www.wsj.com time to read: 1 min

Photo: ARIANA DREHSLER for The Wall Street JournalJust a handful of biotech companies have approved products and growing sales. Merck ’s $10.8 billion acquisition of Prometheus Biosciences, which is developing a promising treatment for inflammatory bowel disease, is giving the entire biotech sector a lift. On Monday, the SPDR S&P Biotech ETF, which has underperformed other growth sectors this year, closed up 4.7%. For the year, the Biotech fund is down 1.4% versus the Nasdaq-100’s gain of 20%.

Globally, IPOs across all sectors nosedived last year after a blockbuster 2021, as aggressive interest rate hikes by central banks to curb inflation put an end to the era of cheap money. In the biotech sector, there were only 47 IPOs last year that raised a total of about $4 billion, compared with 152 offerings in 2021 that had raised over $25 billion. While the XBI is still trading 50% below its February 2021 closing high, analysts believe the downturn in biotech has bottomed out. All we need is one or two biotech IPOs to get good interest and the floodgates will open." Reuters GraphicsThe second half of 2023 is more likely to see a significant step-up in biotech IPOs instead of the first half, as markets await further clarity on potential rate cuts, analysts said.

☆ Why Biotech Is Poised for a Recovery This Year
▼ + stars: | 2023-01-17 | by ( David Wainer | ) www.wsj.com time to read: 1 min

The SPDR S&P Biotech ETF is up 5.9% and the NYSE Arca Pharmaceutical Index is down marginally at the start of the year. The drug industry is now divided between the haves and the have-nots. That wide gap in mood was in stark relief as thousands of industry professionals descended upon San Francisco last week for JPMorgan ‘s big healthcare conference. On one side were giddy pharma executives with plenty of access to cash and their stocks trading near record highs. On the other side, there were cash-strapped small biotech bosses, speaking of layoffs and suspended clinical trials.

☆ Health-care ETFs tend to rise around next week's annual JPMorgan conference. Here's what to know
▼ + stars: | 2023-01-06 | by ( Jesse Pound | ) www.cnbc.com time to read: +3 min

Next week is one of the biggest of the year for health-care investors, and it has historically been a good time to own ETFs that track the industry. The 2023 JPMorgan Health Care Conference is set to kick off next Monday in San Francisco. The sector's S & P 500 weight also sits at a 50-year high of 16%. According to a note from Goldman Sachs, health care is now the second-biggest weight in the S & P 500. Merck , Eli Lilly and AbbVie were a few of the stocks with the biggest positive contributions to the S & P 500 last year, according to Goldman.

☆ Biotech investor Brad Loncar shares 10 predictions for 2023, including a hot new cancer target, Nobel Prize winners, and a biotech founder running for president
▼ + stars: | 2023-01-04 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +14 min

Loncar shared his 2023 forecast, including new drugs, Nobel Prize winners, and more globalization. Brad Loncar isn't expecting a miraculous rebound for the biotech industry in 2023. In an interview with Insider, Loncar shared 10 predictions for biotech in 2023, ranging from Nobel Prize winners and presidential runs to hot cancer targets and bankruptcy worries. 2022 was a rough year for the biotech industry, which once again underperformed the stock market. The industry runs to the next super-hot cancer target: Claudin 18.2In cancer research, drug companies are always on the hunt for the next promising target.

☆ Here are Goldman's best stock option trades for 2023
▼ + stars: | 2022-12-07 | by ( Jesse Pound | ) www.cnbc.com time to read: +3 min

The firm calculated the single stock options with the most upside by comparing the price of an at-the-money call that expires in Jan. 2024 with the hypothetical return if the stock reaches the price target of Goldman's analyst. Call options serve as bets that a stock price will rise above a set strike price during the life of the contract. One benefit of using options is that, if the stock falls, the investors lose only the premium paid for the option. If it continues to climb to Goldman's price target, the call option could deliver a return of nearly 300%, the firm said. A put option is effectively the inverse of a call option and serves as a bet that a stock will fall below a set strike price.

☆ Gene-editing companies are growing thanks to fast-paced science, even as biotech faces a downturn
▼ + stars: | 2022-10-12 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +8 min

CRISPR companies are faring better by producing faster and more dramatic clinical results. A layoff tracker from Fierce Biotech counts at least 90 drug companies that have laid off staff in 2022. Gene-editing biotechs have avoided the brunt of the downturn because of fast clinical successIntellia Therapeutics is developing CRISPR-based gene-editing medicines that could cure diseases. Just in the past month, CRISPR Therapeutics moved into a swanky new headquarters in Boston that can house up to 1,000 people. BeamTo be sure, 2022 hasn't been smooth sailing for the CRISPR companies.

☆ We went inside the lab at Vertex, a company that dodged the market downturn to become one of the best-performing biotechs of 2022
▼ + stars: | 2022-09-21 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +10 min

A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.

Search resuls for: "P Biotech ETF"

22 mentions found